Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group
2021 · BMC Cancer · 14 citations
https://doi.org/10.1186/s12885-021-07922-5